<SEC-DOCUMENT>0001214659-25-005498.txt : 20250407
<SEC-HEADER>0001214659-25-005498.hdr.sgml : 20250407
<ACCEPTANCE-DATETIME>20250407110022
ACCESSION NUMBER:		0001214659-25-005498
CONFORMED SUBMISSION TYPE:	PX14A6G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250407
DATE AS OF CHANGE:		20250407
EFFECTIVENESS DATE:		20250407

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES, INC.
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PX14A6G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19731
		FILM NUMBER:		25816846

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILEAD SCIENCES INC
		DATE OF NAME CHANGE:	19930328

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mercy Investment Services, Inc.
		CENTRAL INDEX KEY:			0001699865
		ORGANIZATION NAME:           	
		EIN:				263224636
		STATE OF INCORPORATION:			MO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		PX14A6G

	BUSINESS ADDRESS:	
		STREET 1:		2039 NORTH GEYER ROAD
		CITY:			ST. LOUIS
		STATE:			MO
		ZIP:			63131
		BUSINESS PHONE:		314-909-4609

	MAIL ADDRESS:	
		STREET 1:		2039 NORTH GEYER ROAD
		CITY:			ST. LOUIS
		STATE:			MO
		ZIP:			63131
</SEC-HEADER>
<DOCUMENT>
<TYPE>PX14A6G
<SEQUENCE>1
<FILENAME>o44255px14a6g.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><B>Notice of Exempt Solicitation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 0; text-indent: -0.5pt"><B>NAME OF REGISTRANT: </B>Gilead Sciences,
Inc</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><B>NAME OF PERSON RELYING ON EXEMPTION: </B>Mercy
Investment Services</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><B>ADDRESS OF PERSON RELYING ON EXEMPTION: </B>2039
N Geyer Rd, Frontenac, MO 63131</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Written materials are submitted pursuant to Rule
14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. <FONT STYLE="color: #1B1B1B">The soliciting person does not beneficially
own more than $5 million of the class of subject securities, and the notice is therefore being provided on a voluntary basis.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.65pt; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt; text-align: center; text-indent: -0.5pt"><B>This is not
a solicitation of authority to vote your proxy. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.55pt 0pt 0.75pt; text-align: center; text-indent: -0.5pt"><B>Please
DO NOT send us your proxy card as it will not be accepted </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.65pt; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 0; text-indent: -0.5pt">We are writing to urge Gilead Sciences,
Inc (&#8220;Gilead&#8221; or the &#8220;Company&#8221;) shareholders to VOTE FOR PROPOSAL 6 (Stockholder Proposal Requesting a Comprehensive
Human Rights Policy and Human Rights Due Diligence Process) on the Company&#8217;s 2025 proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><B>The Shareholder Proposal: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><I>RESOLVED, that shareholders of Gilead Sciences
Inc.(&#8220;Gilead&#8221; or the &#8220;Company&#8221;) urge the board of directors to adopt a comprehensive human rights policy covering
Gilead&#8217;s operations, activities, business relationships, and products, that commits Gilead to respecting internationally recognized
human rights, including the right to health, and to conducting human rights due diligence(&#8220;HRDD&#8221;) to identify, prevent, mitigate,
and remedy the most salient adverse human rights impacts caused by Gilead&#8217;s or a supplier&#8217;s activities. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Introduction:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The right to health is enshrined in international
human rights principles:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 0; text-indent: -0.5pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8226;</FONT></TD><TD STYLE="padding-right: 0.4pt">The Universal Declaration of Human Rights states, &#8220;Everyone has the right to a standard of living
adequate for the health and well-being of himself and of his family, including . . . medical care<SUP>1</SUP>.&#8221;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 36.5pt; text-indent: -0.5pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8226;</FONT></TD><TD STYLE="padding-right: 0.4pt">Article 12.1 of the International Covenant on Economic, Social, and Cultural Rights &#8220;recognize[s]
the right of everyone to the enjoyment of the highest attainable standard of physical and mental health<SUP>2</SUP>.&#8221;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8226;</FONT></TD><TD STYLE="padding-right: 0.4pt">The World Health Organization&#8217;s Constitution states, &#8220;The enjoyment of the highest attainable
standard of health is one of the fundamental rights of every human being without distinction of race, religion, political belief, economic
or social condition<SUP>3</SUP>.&#8221;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 0.5pt; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">_____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><SUP>1</SUP> https://www.ohchr.org/en/human-rights/universal-declaration/translations/english</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><SUP>2</SUP> www.ohchr.org/en/instruments-mechanisms/instruments/international-covenant-economic-social-and-cultural-rights;
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605313</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><SUP>3</SUP> https://www.who.int/about/accountability/governance/constitution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 0; text-indent: -0.5pt">According to the U.N. Special Rapporteur
on the right to health (the &#8220;Special Rapporteur&#8221;), &#8220;[t]he issue of access to medicines is a fundamental component of
the full realization of the right to health. Medical care in the event of sickness and the prevention, and treatment and control of diseases,
depends largely on timely and appropriate access to quality medicines. . . . From a human rights perspective, access to medicines is intrinsically
linked with the principles of equality and non-discrimination, transparency, participation, and accountability<SUP>4</SUP>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 0; text-indent: -0.5pt">Pharmaceutical companies &#8220;ha[ve]
an indispensable role to play in relation to the right to health and access to medicines,&#8221; but their policies have been cited as
a barrier to access<SUP>5</SUP>. The Special Rapporteur&#8217;s &#8220;Human Rights Guidelines for Pharmaceutical Companies in Relation
to Access to Medicines&#8221; (the &#8220;Guidelines&#8221;) recommend that pharmaceutical firms &#8220;should adopt a human rights policy
statement which expressly recognises the importance of human rights generally, and the right to the highest attainable standard of health
in particular&#8221; and &#8220;should integrate human rights, including the right to the highest attainable standard of health, into
the strategies, policies, programmes, projects and activities of the company<SUP>6</SUP>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 0; text-indent: -0.5pt">Specifically, the Guidelines urge that
pharmaceutical companies should &#8220;be as transparent as possible&#8221; with regard to access to medicines; &#8220;disclose all current
advocacy and lobbying positions, and related activities, at the regional, national and international levels, that impact or may impact
upon access to medicines&#8221;; and &#8220;consider all the arrangements at its disposal with a view to ensuring that its medicines are
affordable to as many people as possible<SUP>7</SUP>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 0; text-indent: -0.5pt">Moreover, the UNGPs explicitly state
that companies must conduct human rights due diligence to identify and address adverse salient risks and adverse impacts connected with
their products and services, particularly if the scale and scope of the impacts are likely to be large. Such an approach should certainly
be applied to the Company&#8217;s most important business consideration, that of pricing and access to medicines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 0; text-indent: -0.5pt">In fact, several direct industry peers
have better due diligence and assessment models in place. While not perfect, Sanofi<SUP>8</SUP>, Novartis<SUP>9</SUP>, and Novo Nordisk<SUP>10</SUP>
all disclose processes that describe their commitment not just to a robust human rights policy, but diligence and assessment of that policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 0; text-indent: -0.5pt">Additionally, addressing the costs
of human rights violations and health inequity may help protect the company&#8217;s shareholders from the economy-wide costs and
macroeconomic threats related to human rights violations. A recent paper by Deloitte found that &#8220;addressing health equity gaps
across the United States could add US$2.8 trillion to the US gross domestic product by 2040, representing a 9.5% increase over
current economic projections<SUP>11</SUP>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">_____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><SUP>4</SUP> https://www.ohchr.org/en/special-procedures/sr-health/access-medicines-and-right-health</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>5</SUP> SYMPOSIUM ARTICLE: Human Rights Responsibilities of Pharmaceutical
Companies in Relation to Access to Medicines, 40 J.L. Med. &amp; Ethics 220 (Summer 2012)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><SUP>6</SUP> https://www.ohchr.org/Documents/Issues/Health/GuidelinesForPharmaceuticalCompanies.doc,
paras 1-2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><SUP>7</SUP> Guidelines, paras. 6, 17, 33</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><SUP>8</SUP> https://www.sanofi.com/assets/dotcom/content-app/documents/Human_right_activities_EN.pdf</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><SUP>9</SUP> https://www.novartis.com/esg/ethics-risk-and-compliance/human-rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><SUP>10</SUP> https://www.novonordisk.com/content/dam/nncorp/global/en/sustainable-business/pdfs/esg-portal/2024/novo-nordisk-human-rights-report-2023.pdf</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><SUP>11</SUP> https://www2.deloitte.com/us/en/insights/industry/health-care/health-equity-economic-impact.html</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><B>Regulatory, legal, and financial risks persist:
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 0; text-indent: -0.5pt">Gilead continues to suffer from several
high-profile controversies which present significant risk to investors. Gilead has been criticized for limiting access to its lifesaving
HIV medications. Its recent deal licensing to six generics manufacturers the right to sell the &#8220;game-changing&#8221;<SUP>12</SUP>
long-acting lenacapavir has been faulted for side stepping the Medicines Patent Pool and for its inadequate geographic reach.<SUP>13</SUP>
Lenacapavir&#8217;s annual U.S. price of over $40,000 also inhibits access.<SUP>14</SUP> Gilead recently settled one case and faces a
much larger one claiming that its delay in seeking approval for a safer form of tenofovir out of a desire to fully exploit its exclusivity
period for its already FDA-approved but much more toxic form of the drug caused kidney and bone damage that killed patients.<SUP>15</SUP>
A HRDD process could potentially have flagged these products as risky and the Company could have taken proactive steps to keep these lawsuits
from happening.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><B>The statement in opposition is insufficient:
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 0; text-indent: -0.5pt">The statement of opposition states that
&#8220;A Separate Human Rights Policy is Redundant and Unnecessary&#8221;. It then lists various codes of conduct and other reporting
unrelated to human rights. The fact that they are out of step with not only the peer companies listed earlier, but also Bristol Myers
Squibb<SUP>16</SUP>, Pfizer<SUP>17</SUP>, and Moderna,<SUP>18</SUP> illustrates that the industry understands a supplier code of conduct
is not a sufficient replacement for a robust human rights policy. In fact, the supplier code&#8217;s requirement that suppliers conduct
HRDD to identify and address human rights risks would not identify adverse impacts of Gilead&#8217;s own operations; also, suppliers&#8217;
incentives, including those created by purchasing practices, may discourage them from undertaking robust HRDD.<SUP>19</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 0; text-indent: -0.5pt">The Company says that &#8220;We believe
that human rights is an important issue that is not static,&#8221; but then provides no disclosures around any process that would demonstrate
that sentiment to be true. While the commitments are laudable, they ring hollow when the Company doesn&#8217;t lean into this very commitment
to examine the core of its business &#8211; which is getting its products to patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">_____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>12</SUP></FONT>
https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2024/july/20240710_le</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>13</SUP></FONT>
https://www.citizen.org/news/hiv-breakthrough-drug-licensing-deal-marks-significant-but-flawed-step-for-access/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>14</SUP></FONT>
https://msfaccess.org/activists-aids2024-demand-break-gileads-lenacapavir-monopoly-gileads-price-100000-higher-target</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>15</SUP></FONT>
https://www.statnews.com/2024/08/16/gilead-suit-patent-hopping-hiv-treatment/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>16</SUP></FONT>
https://www.bms.com/assets/bms/us/en-us/pdf/bms-human-rights-global-position.pdf</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>17</SUP></FONT>
https://cdn.pfizer.com/pfizercom/about/Human_Rights_Policy_Statement_2024.pdf</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>18</SUP></FONT>
https://static.modernatx.com/pm/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867/1b007783-9e91-43c7-85d0-05d05fea2c4b/1b007783-9e91-43c7-85d0-05d05fea2c4b_viewable_rendition__v.pdf</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>19</SUP></FONT>
https://www.ohchr.org/sites/default/files/documents/publications/guidingprinciplesbusinesshr_en.pdf</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"><B>Conclusion:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt">Lack of access to medicines poses a
systemic threat to public health and the economy. When the availability of lifesaving drugs is compromised, the entire economy suffers.
And when the economy suffers, investors lose. Gilead claims that<SUP>20</SUP>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.65pt; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><I>We understand that making the world a healthier
place for all people means going beyond the medicine to help remedy health inequities and other barriers to care. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.55pt 0pt 0; text-align: justify; text-indent: 0in">We believe that to
fulfill this commitment, the company must commit to HRDD, and disclose the results of that diligence, on the impacts of its operations,
activities, business relationships, and products related to access to medicines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4pt 0pt 0; text-indent: -0.5pt">For these reasons, we ask you to vote
<B>FOR Proposal 6</B><FONT STYLE="color: red">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt; text-align: center; text-indent: -0.5pt"><B>This is not
a solicitation of authority to vote your proxy. </B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Please DO NOT send us your proxy
card as it will not be accepted. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">_____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><SUP>20</SUP> https://www.gilead.com/responsibility/health-equity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
